Price List - Veppanu - Breast Cancer Agents - Estrogen Receptor Antagonist.xlsx
XLSX spreadsheet 45 KB Posted
- Solicitation number
- HT9402-26-Q-9304
- Issued by
-
Defense Health Agency
About this file
This is a price list template for the Department of War (DoW) Pharmacy Uniform Formulary Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) for breast cancer agents in the Estrogen Receptor Antagonist subclass. The solicitation number is HT9402-26-Q-9304, and quotes are due by July 27, 2026, for review at the August 5-6, 2026 P&T Committee meeting. The price list contains multiple appendices for up to ten newly approved drugs, with templates for manufacturers to submit pricing across three distinct contract vehicles: BPA UF (for Uniform Formulary placement at Military Treatment Facilities and Mail Order), ADP non-FAMP Discount (for TRICARE Retail refunds based on Federal Ceiling Price calculations), and ADP WAC Discount (for products without FCP using Wholesale Acquisition Cost pricing). Manufacturers must submit fully executed signature pages, quote review checklists, and pricing information for both Uniform Formulary scenarios (Tier 1 and non-formulary) and Additional Discount Program scenarios (Tier 2 and Tier 3 classifications).
The pricing structure requires per-unit pricing that remains consistent across all package sizes within a given dosage form and strength. For BPA submissions, manufacturers provide price per NDC package size and price per unit. For non-FAMP ADP submissions, manufacturers quote the Non-FAMP drug price, additional offered refund percentages, and standard refund calculations based on the Federal Ceiling Price. For WAC-based ADP submissions, manufacturers provide WAC discount percentages that remain static throughout the agreement term. Agents may be designated as step-therapy preferred or non-preferred based on quote submissions and P&T Committee selections. Prior Authorization may apply, and agents may be considered for preferential reimbursement to encourage high-value products or complete exclusion from the TRICARE pharmacy benefit program. The Defense Health Agency administers these agreements under 10 U.S.C. 1074g and 32 CFR Section 199.21.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| A-1 Price List - Lynavoy - Gastrointestinal-2 Agents - NA.xlsx | XLSX spreadsheet | |
| Amendment 0001.pdf | ||
| Price List - Lynavoy - Gastrointestinal-2 Agents - NA.xlsx | XLSX spreadsheet | |
| Price List - Xtoro - Antibiotics - Quinolones.xlsx | XLSX spreadsheet | |
| Price List - Atoncy - ADHD Agents - Non-stimulants.xlsx | XLSX spreadsheet | |
| Price List - Duloxetine - Antidepressants And Non-opioid Pain Syndrome Agents - SNRI.xlsx | XLSX spreadsheet | |
| RFQ HT9402-26-Q-9304 NAD.pdf | ||
| Price List - Hepcludex - Hepatitis D Agent - NA.xlsx | XLSX spreadsheet | |
| Price List - Filkri - White Blood Cell Stimulants - Filgrastims.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ NAD.pdf | ||
| Price List - Xocova - Antivirals - FDA Approved COVID Therapeutics.xlsx | XLSX spreadsheet | |
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| Price List - Baxfendy - Diuretics - Mineralocorticoid Receptor Antagonists.xlsx | XLSX spreadsheet |
Show all 13
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the August 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 |
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (i.e. after-step).
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264BCERG1UF1M | Uniform | |||
| Formulary | 1 or more | NO QUOTE | |||
| 264BCERAG1NF1M | Non- | ||||
| Formulary | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #2 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264BCERG1UF1M | Uniform | |||
| Formulary | 1 or more | NO QUOTE | |||
| 264BCERAG1NF1M | Non- | ||||
| Formulary | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264BCERG1UF1M | Uniform | |||
| Formulary | 1 or more | NO QUOTE | |||
| 264BCERAG1NF1M | Non- | ||||
| Formulary | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264BCERG1UF1M | Uniform | |||
| Formulary | 1 or more | NO QUOTE | |||
| 264BCERAG1NF1M | Non- | ||||
| Formulary | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264BCERG1UF1M | Uniform | |||
| Formulary | 1 or more | NO QUOTE | |||
| 264BCERAG1NF1M | Non- | ||||
| Formulary | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264BCERG1UF1M | Uniform | |||
| Formulary | 1 or more | NO QUOTE | |||
| 264BCERAG1NF1M | Non- | ||||
| Formulary | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264BCERG1UF1M | Uniform | |||
| Formulary | 1 or more | NO QUOTE | |||
| 264BCERAG1NF1M | Non- | ||||
| Formulary | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264BCERG1UF1M | Uniform | |||
| Formulary | 1 or more | NO QUOTE | |||
| 264BCERAG1NF1M | Non- | ||||
| Formulary | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264BCERG1UF1M | Uniform | |||
| Formulary | 1 or more | NO QUOTE | |||
| 264BCERAG1NF1M | Non- | ||||
| Formulary | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 264BCERG1UF1M | Uniform | |||
| Formulary | 1 or more | NO QUOTE | |||
| 264BCERAG1NF1M | Non- | ||||
| Formulary | 1 or more | NO QUOTE | |||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (non-FAMP Discount)
| UF ADP Appendix for the August 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 |
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (i.e. after-step).
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote | ||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote | ||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | |||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (WAC Discount)
| UF ADP Appendix for the August 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 |
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (i.e. after-step).
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DoW Uniform Formulary Class: | BREAST CANCER AGENTS | P&T Committee Meeting: | August 5-6, 2026 | ||
| DoW Uniform Formulary Subclass: | ESTROGEN RECEPTOR ANTAGONIST | Quotes due: | July 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 264BCERG1T21M | Tier 2 | 1 or more | |
| 264BCERG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
File details come from the government source that posted it. Updated .